Loading...
Market
What will be Candel Therapeutics' market cap by end of 2025?
3
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Financial reports and stock market data
Story
Candel Therapeutics' CAN-2409 Succeeds in Phase 3 Prostate Cancer Trial, Shares Soar
Dec 11, 2024, 12:48 PM
Candel Therapeutics announced that its experimental immunotherapy, CAN-2409, met the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival. Following the announcement, the company's shares more than doubled in value in premarket trading. CAN-2409 is an oncolytic virus designed to stimulate the immune system to attack cancer cells. The trial's success marks a significant milestone for Candel Therapeutics, potentially paving the way for further development and regulatory approval of the treatment.
View original story
Similar markets
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Below $1 Billion • 25%
$1 Billion to $2 Billion • 25%
$2 Billion to $3 Billion • 25%
Above $3 Billion • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Below $15 billion • 25%
$15-$19.99 billion • 25%
$20-$24.99 billion • 25%
$25 billion or above • 25%
Yes • 50%
No • 50%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%